Mitchell Smith, MD, PhD; GW Cancer Center; 5Live #ASH20
Key insights from the 2020 Annual Hematology meeting in Lymphoma
Michael Wang, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
Key Insights on Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
Martin Hutchings, MD, PhD Rigshospitalet, Copenhagen Denmark 5Live #ASCO20
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)